The Europe Rabies Vaccine Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Rabies Vaccine Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $101 Million by 2030. The UK market is exhibiting a CAGR of 3.2% during (2023 - 2030). Additionally, The France market would experience a CAGR of 4.9% during (2023 - 2030).
Professionals working in high-risk occupations, such as wildlife researchers, animal handlers, and veterinarians, may receive these vaccines to mitigate the risk of exposure during their work. This targeted vaccination strategy helps protect individuals regularly in close contact with animals, who may be more likely to encounter the rabies virus. These vaccines are crucial in emergency response situations, such as outbreaks or clusters of rabies cases.
Furthermore, dogs are the primary reservoirs and transmitters of the rabies virus to humans. Unvaccinated dogs carry a considerable risk of rabies transmission through bites in regions where the disease is endemic. The prevalence of dog bites, especially in areas with a high population of stray or unvaccinated dogs, underscores the urgent need for effective rabies vaccination programs.
Rabies is a zoonotic disease that threatens public health in France. The occurrence of rabies cases prompts public health authorities to implement preventive measures, including the vaccination of domestic animals and public awareness campaigns to reduce the risk of human exposure in France. Like many European countries, France has legal requirements for rabies vaccination of domestic animals, particularly dogs and cats. Veterinarians are pivotal in recommending and administering these vaccines to domestic animals in France. The increased incidence of rabies cases may lead to heightened awareness among pet owners, who are more likely to follow veterinary recommendations for vaccination in France. Thus, all these factors will uplift the regional market’s expansion in the coming years.
Free Valuable Insights: The Global Rabies Vaccine Market will Hit USD 1.6 Billion by 2030, at a CAGR of 4.5%
Based on Prophylaxis Type, the market is segmented into Post-exposure Prophylaxis, and Pre-exposure prophylaxis. Based on End User, the market is segmented into Hospitals, Veterinary Clinics, and Others. Based on Application, the market is segmented into Human, and Animal. Based on Product Type, the market is segmented into Chick Embryo Cells Rabies Vaccine, Human Diploid Cell Vaccine, Vero cell rabies vaccine, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Prophylaxis Type
By End User
By Application
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
